|
Shopping Cart
Your Cart is currently empty.
Member Login
Review
Functional Dyspepsia : still a serious challenge for medical practitioners and new drug investigators ? A Belgian, French, German and Hungarian opinionPrice: €10,00 |
|
The diagnosis of Functional Dyspepsia is based on the identification
of long term specific symptoms and the absence of organic
lesions. Many pathophysiological mechanisms are intricate and, at
least, partially responsible for the syndrome. Widely accepted
technical procedures for the identification of these mechanisms are
missing. The final etiopathology is not yet established. The relationship
between symptoms and putative mechanisms is unclear.
At the moment of the prescription, the physician faces a real therapeutic
gap. Moreover, Functional Dyspepsia is an evolving area of
study and knowledge has to be updated regularly. As a result, consultations
for Functional Dyspepsia are usually very challenging
and patients look desperately for medical support. It is likely that
this disease is both under-diagnosed and under-treated. Classifying
patients into symptomatic subgroups is a promising
approach proposed by Rome III. It is assumed that these subgroups
are based on different pathophysiological mechanisms, and
may allow for more specific therapeutic approaches. However the
assessment of the symptomatic profiles of patients is time-consuming.
It is also a risky process, because the Rome III subgroups have
yet to be validated. There are currently no translations of the definitions
in the different European languages. Interviews of the
patients are biased by cultural, educational and subjective factors.
Identification of suitable subjects for clinical trials is uneasy for
the same reasons and can explain several recent Research and
Development (R&D) failures. Therefore, there is a need for an
updated, step by step approach, a real diagnostic algorithm of the
consultation including the use of simple, clear, universal and crosscultural
validated tools, as word-figure questionnaires, designed to
establish the symptomatic profiles of the patients. (Acta gastroenterol.
belg., 2010, 73, 360-365. [Product Details...] |
Gastrointestinal stromal tumors: Review on morphology, molecular pathology, diagnostics, prognosis and treatment optionsPrice: €10,00 |
|
Gastrointestinal stromal tumors (GISTs) are the most common
non-epithelial mesenchymal tumors of the gastrointestinal tract.
GISTs represent a specific group of mesenchymal tumors with
uncertain biological behaviors. These tumors are assumed to originate
from progenitor cells, usually unable to self-regenerate,
which differentiate towards Cajal cells. Apart from common
GISTs that occur predominantly in adulthood, a heterogeneous
group of tumors has been described that are morphologically identical
with GIST, but have a specific clinical presentation and biological
properties.
Approximately 30% of newly diagnosed GISTs are malignant
or have a high potential for malignancy. Currently, GISTs are routinely
identified with histological, immunohistochemical, and
molecular genetic assays. However, clinical diagnoses, particularly
of small or intramural GISTs, might be difficult. The most useful
techniques for imaging and monitoring disease progression are
endoscopic examinations and fused PET/CT imaging. Surgical
treatment is the first-line treatment and the only method that
might lead to full remission in patients with a primary GIST.
There is currently no consensus on the issues of whether to perform
resections in patients with positive margins or resections of
metastases. Endoscopic resection could represent a relatively simple
and less aggressive alternative as compared to traditional
surgery in the treatment of small sized GISTs. Biological therapy
with imatinib mesylate is recommended for patients with newly
diagnosed, locally advanced, inoperable, or metastasizing gastrointestinal
GISTs that express the c-KIT protein. Treatment
may reduce a primary tumor to a size small enough for surgical
excision. Current research is focusing on the development of new
therapies for the treatment of advanced disease and/or disease
prophylaxis. (Acta gastroenterol. belg., 2010, 73, 349-359). [Product Details...] |
- «« Start
- « Prev
- 1
- Next »
- End »»
Acta gastroenterologica is abstracted/indexed in Current Contents, Excerpta Medica, Index medicus, ISI.
Published by © Universa Press, Wetteren, Belgium. All rights reserved.
Published by © Universa Press, Wetteren, Belgium. All rights reserved.